Literature DB >> 21138526

COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1.

T E Riehl1, L He, L Zheng, S Greco, D M Tollefsen, W F Stenson.   

Abstract

BACKGROUND: We found a high incidence of thrombotic deaths in COX-1(+/-)COX-2(-/-) mice and sought to define the mechanism of these events. The cyclooxygenase products thromboxane A(2) and prostacyclin are important in the regulation of coagulation but their role in fibrinolysis is largely unexplored. PAI-1 blocks fibrinolysis by inhibiting plasminogen activator. AIM: Our objective was to explain the mechanism of increased thrombosis associated with the COX-1(+/-)COX-2(-/-) genotype.
METHODS: Carotid artery occlusion times were measured after photochemical injury. PAI-1 levels were measured in the plasma by ELISA. PAI-1 levels in the aorta were measured by RT-PCR and Western blotting. Urinary metabolites of Thromboxane A(2) and prostacyclin were measured by ELISA.
RESULTS: The COX-1(+/-)COX-2(-/-) genotype is associated with a decreased time to occlusion in the carotid artery thrombosis model (30 ± 5 minutes vs 60 ± minutes in wild type, p<.001). The COX-1(-/-)COX-2(+/+), COX-1(+/-)COX-2(+/-) and COX-1(+/-)COX-2(+/+) all had occlusion times similar to wild type. COX-1(+/+)COX-2(-/-) had a prolonged occlusion time. COX-1(+/-)COX-2(-/-) had increased PAI-1 levels in the plasma and aorta and with a prolonged euglobulin lysis time (37.4 ± 10.2 hours vs 15.6 ± 9.8 hours in wild type, p<.004). The decreased time to occlusion in the COX-1(+/-)COX2(-/-) mice was normalized by an inhibitory antibody to PAI-1 whereas the antibody had no effect on the time to occlusion in wild type mice.
CONCLUSION: The COX-1(+/-)COX-2(-/-) genotype is associated with a shortened time to occlusion in the carotid thrombosis model and the shortened time to occlusion is mediated through increased PAI-1 levels resulting in decreased fibrinolysis.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21138526      PMCID: PMC3687774          DOI: 10.1111/j.1538-7836.2010.04156.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  41 in total

1.  Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts.

Authors:  N L Baenziger; P R Becherer; P W Majerus
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

2.  Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

Authors:  W P Fay; A D Shapiro; J L Shih; R R Schleef; D Ginsburg
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

3.  Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides.

Authors:  P Needleman; S Moncada; S Bunting; J R Vane; M Hamberg; B Samuelsson
Journal:  Nature       Date:  1976-06-17       Impact factor: 49.962

4.  Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

Authors:  J E Dinchuk; B D Car; R J Focht; J J Johnston; B D Jaffee; M B Covington; N R Contel; V M Eng; R J Collins; P M Czerniak
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

5.  Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

Authors:  S G Morham; R Langenbach; C D Loftin; H F Tiano; N Vouloumanos; J C Jennette; J F Mahler; K D Kluckman; A Ledford; C A Lee; O Smithies
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

6.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

7.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors:  P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays.

Authors:  C Créminon; A Habib; J Maclouf; P Pradelles; J Grassi; Y Frobert
Journal:  Biochim Biophys Acta       Date:  1995-02-09

9.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

10.  Inter-relationships between vascular thromboxane and prostacyclin synthesis.

Authors:  M J James; J A Walsh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1988-02       Impact factor: 4.006

View more
  1 in total

1.  Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Authors:  Chao Fang; Evi Stavrou; Alec A Schmaier; Nadja Grobe; Mariana Morris; Andrew Chen; Marvin T Nieman; Gregory N Adams; Gretchen LaRusch; Yihua Zhou; Matthew L Bilodeau; Fakhri Mahdi; Mark Warnock; Alvin H Schmaier
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.